Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920629 | 0.84 | CYP3A4 (0.45) | HTR5AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3050675 | 0.77 | LMNA (0.46) | CYP3A4CYP2C19HTT | |
| SCHEMBL1921273 | 0.73 | HTR1A (0.42) | HTR5AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1919918 | 0.73 | PSMB1 (0.53) | — | |
| SCHEMBL3517454 | 0.73 | TNF (0.43) | HTR2CHTR2A | |
| SCHEMBL9685430 | 0.72 | USP19 (0.48) | CYP3A4CYP2C19TP53CYP1A2CYP2D6 | |
| SCHEMBL3049159 | 0.72 | KDM4E (0.42) | CYP3A4CYP2C19CYP2D6HTTDRD2 | |
| SCHEMBL28499890 | 0.69 | HTR3E (0.49) | HTR5AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9396666 | 0.69 | HTR3E (0.51) | HTR5AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13046538 | 0.69 | TNF (0.56) | CYP3A4CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2010031707-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | HTR5A 337/4885HTR3E 261/4885HTR3B 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.